Platelet activation triggered by Chlamydia pneumoniae is antagonized by 12-lipoxygenase inhibitors but not cyclooxygenase inhibitors

European Journal of Pharmacology

Volumn 566, Issue 1-3, 2007, Pages 20-27

  Kälvegren, Hanna ^a   Andersson, Johanna ^a   Grenegård, Magnus ^a   Bengtsson, Torbjörn ^a  

^a Cardiovascular Inflammation Research Centre   (Sweden)

Author keywords

Aggregation; Chlamydia pneumoniae; Cyclooxygenase; Lipoxygenase; Platelet

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE; ARACHIDONATE 12 LIPOXYGENASE; BAICALEIN; CANGRELOR; CINNAMYL 3,4 DIHYDROXY ALPHA CYANOCINNAMATE; COLLAGEN; CYCLOOXYGENASE 2 INHIBITOR; GINKGOLIDE B; GUANYLATE CYCLASE INHIBITOR; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE DONOR; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR; PURINERGIC RECEPTOR BLOCKING AGENT; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG INHIBITION; DRUG RESPONSE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; THROMBOSIS;

ADENOSINE TRIPHOSPHATE; ADULT; ARACHIDONATE 12-LIPOXYGENASE; ASPIRIN; CAFFEIC ACIDS; CELL LINE, TUMOR; CHLAMYDOPHILA PNEUMONIAE; CYCLIC AMP; CYCLIC GMP; CYCLOOXYGENASE INHIBITORS; FLAVANONES; HUMANS; PIROXICAM; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION; RECEPTORS, PURINERGIC P2;

EID: 34249274950     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.03.024     Document Type: Article

References (47)

1. Asplund Persson A., Zalavary S., Lindstrom E., Whiss P.A., Bengtsson T., and Grenegard M. Cross-talk between adenosine and the oxatriazole derivative GEA 3175 in platelets. Eur. J. Pharmacol. 517 (2005) 149-157
2. Barrington W.W., Jacobson K.A., Hutchison A.J., Williams M., and Stiles G.L. Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 6572-6576
3. Bengtsson T., Zalavary S., Stendahl O., and Grenegard M. Release of oxygen metabolites from chemoattractant-stimulated neutrophils is inhibited by resting platelets: role of extracellular adenosine and actin polymerization. Blood 87 (1996) 4411-4423
4. Bonin F., Ryan S.D., Migahed L., Mo F., Lallier J., Franks D.J., Arai H., and Bennett S.A. Anti-apoptotic actions of the platelet-activating factor acetylhydrolase I alpha2 catalytic subunit. J. Biol. Chem. 279 (2004) 52425-52436
5. Butenko I.G., Gladtchenko S.V., and Galushko S.V. Anti-inflammatory properties and inhibition of leukotriene C4 biosynthesis in vitro by flavonoid baicalein from Scutellaria baicalensis Georgy roots. Agents Actions 39 (1993) C49-C51 Spec No
6. Campbell L.A., and Kuo C.C. Chlamydia pneumoniae-an infectious risk factor for atherosclerosis?. Nat. Rev. Microbiol. 2 (2004) 23-32
7. Carty T.J., Stevens J.S., Lombardino J.G., Parry M.J., and Randall M.J. Piroxicam, a structurally novel anti-inflammatory compound. Mode of prostaglandin synthesis inhibition. Prostaglandins 19 (1980) 671-682
8. Chattaraj S.C. Cangrelor AstraZeneca. Curr. Opin. Investig. Drugs 2 (2001) 250-255
9. Cho H., Ueda M., Tamaoka M., Hamaguchi M., Aisaka K., Kiso Y., Inoue T., Ogino R., Tatsuoka T., and Ishihara T. Novel caffeic acid derivatives: extremely potent inhibitors of 12-lipoxygenase. J. Med. Chem. 34 (1991) 1503-1505
10. Conley P.B., and Delaney S.M. Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis. Curr. Opin. Hematol. 10 (2003) 333-338
11. Davis K.L., Martin E., Turko I.V., and Murad F. Novel effects of nitric oxide. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 203-236
12. Feoktistov I.A., Paul S., Hollister A.S., Robertson D., and Biaggioni I. Role of cyclic AMP in adenosine inhibition of intracellular calcium rise in human platelets. Comparison of adenosine effects on thrombin- and epinephrine-induced platelet stimulation. Am. J. Hypertens. 5 (1992) 147-153
13. Gachet C. Regulation of platelet functions by P2 receptors. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 277-300
14. Gaynor B.J., and Constantine J.W. The effect of piroxicam on platelet aggregation. Experientia 35 (1979) 797-798
15. Geiger J., Nolte C., Butt E., Sage S.O., and Walter U. Role of cGMP and cGMP-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human platelets. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 1031-1035
16. Grenegard M., Gustafsson M.C., Andersson R.G., and Bengtsson T. Synergistic inhibition of thrombin-induced platelet aggregation by the novel nitric oxide-donor GEA 3175 and adenosine. Br. J. Pharmacol. 118 (1996) 2140-2144
17. Gutierrez J., Linares-Palomino J., Lopez-Espada C., Rodriguez M., Ros E., Piedrola G., and del Maroto M.C. Chlamydia pneumoniae DNA in the arterial wall of patients with peripheral vascular disease. Infection 29 (2001) 196-200
18. Hammarstrom S. Selective inhibition of platelet n-8 lipoxygenase by 5,8,11-eicosatriynoic acid. Biochim. Biophys. Acta 487 (1977) 517-519
19. Hauer A.D., de Vos P., Peterse N., ten Cate H., van Berkel T.J., Stassen F.R., and Kuiper J. Delivery of Chlamydia pneumoniae to the vessel wall aggravates atherosclerosis in LDLr-/-mice. Cardiovasc. Res. 69 (2006) 280-288
20. Hirono S., Dibrov E., Hurtado C., Kostenuk A., Ducas R., and Pierce G.N. Chlamydia pneumoniae stimulates proliferation of vascular smooth muscle cells through induction of endogenous heat shock protein 60. Circ. Res. 93 (2003) 710-716
21. Horiuchi H. Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problems. Ann. Med. 38 (2006) 162-172
22. Kalayoglu M.V., and Byrne G.I. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J. Infect. Dis. 177 (1998) 725-729
23. Kalvegren H., Majeed M., and Bengtsson T. Chlamydia pneumoniae binds to platelets and triggers P-selectin expression and aggregation: a causal role in cardiovascular disease?. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1677-1683
24. Kalvegren H., Bylin H., Leanderson P., Richter A., Grenegard M., and Bengtsson T. Chlamydia pneumoniae induces nitric oxide synthase and lipoxygenase-dependent production of reactive oxygen species in platelets. Effects on oxidation of low density lipoproteins. Thromb. Haemost. 94 (2005) 327-335
25. Katoh A., Ikeda H., Murohara T., Haramaki N., Ito H., and Imaizumi T. Platelet-derived 12-hydroxyeicosatetraenoic acid plays an important role in mediating canine coronary thrombosis by regulating platelet glycoprotein IIb/IIIa activation. Circulation 98 (1998) 2891-2898
26. Krull M., Maass M., Suttorp N., and Rupp J. Chlamydophila pneumoniae. Mechanisms of target cell infection and activation. Thromb. Haemost. 94 (2005) 319-326
27. Mangin P., Ohlmann P., Eckly A., Cazenave J.P., Lanza F., and Gachet C. The P2Y1 receptor plays an essential role in the platelet shape change induced by collagen when TxA2 formation is prevented. J. Thromb. Haemost. 2 (2004) 969-977
28. Michibayashi T. Platelet aggregation and vasoconstriction related to platelet cyclooxygenase and 12-lipoxygenase pathways. J. Atheroscler. Thromb. 12 (2005) 154-162
29. Molestina R.E., Miller R.D., Ramirez J.A., and Summersgill J.T. Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes. Infect. Immun. 67 (1999) 1323-1330
30. Mussa F.F., Chai H., Wang X., Yao Q., Lumsden A.B., and Chen C. Chlamydia pneumoniae and vascular disease: an update. J. Vasc. Surg. 43 (2006) 1301-1307
31. Nunez D., Chignard M., Korth R., Le Couedic J.P., Norel X., Spinnewyn B., Braquet P., and Benveniste J. Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988. Eur. J. Pharmacol. 123 (1986) 197-205
32. Nylander S., Mattsson C., Ramstrom S., and Lindahl T.L. The relative importance of the ADP receptors, P2Y12 and P2Y1, in thrombin-induced platelet activation. Thromb. Res. 111 (2003) 65-73
33. O'Flaherty J.T., Thomas M.J., Hammett M.J., Carroll C., McCall C.E., and Wykle R.L. 5-l-hydroxy-6,8,11,14-eicosatetraenoate potentiates the human neutrophil degranulating action of platelet-activating factor. Biochem. Biophys. Res. Commun. 111 (1983) 1-7
34. Olivera-Severo D., Wassermann G.E., and Carlini C.R. Bacillus pasteurii urease shares with plant ureases the ability to induce aggregation of blood platelets. Arch. Biochem. Biophys. 452 (2006) 149-155
35. Paul S., Feoktistov I., Hollister A.S., Robertson D., and Biaggioni I. Adenosine inhibits the rise in intracellular calcium and platelet aggregation produced by thrombin: evidence that both effects are coupled to adenylate cyclase. Mol. Pharmacol. 37 (1990) 870-875
36. Redecke V., Dalhoff K., Bohnet S., Braun J., and Maass M. Interaction of Chlamydia pneumoniae and human alveolar macrophages: infection and inflammatory response. Am. J. Respir. Cell Mol. Biol. 19 (1998) 721-727
37. Roberts D.E., McNicol A., and Bose R. Mechanism of collagen activation in human platelets. J. Biol. Chem. 279 (2004) 19421-19430
38. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
39. Saikku P., Leinonen M., Mattila K., Ekman M.R., Nieminen M.S., Makela P.H., Huttunen J.K., and Valtonen V. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 2 (1988) 983-986
40. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220 (1983) 568-575
41. Sands W.A., and Palmer T.M. Adenosine receptors and the control of endothelial cell function in inflammatory disease. Immunol. Lett. 101 (2005) 1-11
42. Schrammel A., Behrends S., Schmidt K., Koesling D., and Mayer B. Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol. Pharmacol. 50 (1996) 1-5
43. Sekiya K., and Okuda H. Selective inhibition of platelet lipoxygenase by baicalein. Biochem. Biophys. Res. Commun. 105 (1982) 1090-1095
44. Setty B.N., Werner M.H., Hannun Y.A., and Stuart M.J. 15-Hydroxyeicosatetraenoic acid-mediated potentiation of thrombin-induced platelet functions occurs via enhanced production of phosphoinositide-derived second messengers-sn-1,2-diacylglycerol and inositol-1,4,5-trisphosphate. Blood 80 (1992) 2765-2773
45. van Kuppeveld F.J., van der Logt J.T., Angulo A.F., van Zoest M.J., Quint W.G., Niesters H.G., Galama J.M., and Melchers W.J. Genus- and species-specific identification of mycoplasmas by 16S rRNA amplification. Appl. Environ. Microbiol. 58 (1992) 2606-2615
46. Wykle R.L. Arachidonate remodeling and PAF synthesis in human neutrophils. In: Fonteh A.N., and Wykle R.L. (Eds). Arachidonate Remodeling and Inflammation (2004), Birkhauser Verlag, Basel 73-82
47. Zembowicz A., Dudek R.D., Radziszewski W., Swierkosz T.A., Trybulec M., and Gryglewski R.J. Vasorelaxant and platelet-suppressant potencies of four NO-donors. Pol. J. Pharmacol. Pharm. 42 (1990) 275-281